AsclepiX Therapeutics Revenue and Competitors

VISION ABOVE AND BEYOND AsclepiX Therapeutics is revolutionizing the treatment of retinal diseases and cancer with a singular focus on the design, development, and delivery of novel peptides with the power to inhibit proven key disease pathways. Our peptide drug candidates tap into the body's powerful mechanisms of maintaining homeostasis, the fundamental principle of biology to seek and maintain a condition of equilibrium or stability. Using computational biology and artificial intelligence to identify potent peptide regulators of vascular homeostasis, our clinical candidate peptides harness these naturally existing self-regulating mechanisms that the body uses to maintain homeostasis and thus restore and maintain health. Our lead candidate, AXT107 inhibits VEGF and activates Tie 2, the only two clinically validated pathways for the treatment of serious diseases of the retina. And remarkably, AXT107 forms a gel when injected into the eye, releasing clinically active levels of the peptide slowly over many months, potentially allowing the product to be dosed only 1 or 2 times per year rather than every two to three months as required for many of the products approved or in clinical development by others for the treatment of wet AMD and DME.